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 Abstract 
 The SYMPLICITY studies showed that renal denervation (RDN) is feasible as novel treatment for resistant hyperten-
sion. However, RDN is a costly and invasive procedure, the long-term effi cacy and safety of which has not yet been 
proven. Therefore, we designed the INSPiRED trial to compare the blood pressure lowering effi cacy and safety of RDN 
vs usual medical therapy. INSPiRED is a randomized controlled trial enrolling 240 treatment-resistant hypertensive 
patients at 16 expert hypertension centres in Belgium. Eligible patients, aged 20 – 69 years old, have a 24-h ambulatory 
blood pressure of 130 mmHg systolic or 80 mmHg diastolic or more, while taking at least three antihypertensive drugs. 
They are randomized to RDN (EnligHTN TM , SJM system) plus usual care (intervention group) or usual care alone 
(control group) in a ratio of 1:1. The primary endpoints for effi cacy and safety, measured after 6 months, are the 
baseline-adjusted between-group differences in 24h systolic blood pressure and in glomerular fi ltration rate as estimated 
by the Chronic Kidney Disease Epidemiology Collaboration equation. Follow-up will continue up to 36 months after 
randomization. INSPiRED is powered to demonstrate a 10-mmHg difference in systolic blood pressure between rand-
omized groups with a two-sided  p -value of 0.01 and 90% power. It will generate long-term effi cacy and safety 
data, identify the subset of treatment-resistant hypertensive patients responsive to RDN, provide information on cost-
effectiveness, and by doing so INSPiRED will inform guideline committees and health policy makers.  Trial registration: 
ClinicalTrials.gov Identifi er: NCT 01505010. 
 Key Words:  Ambulatory blood pressure ,  randomized controlled trial ,  renal denervation ,  resistant hypertension 
 Introduction and rationale 
 Resistant hypertension is a blood pressure that 
remains above goal in spite of the concomitant use 
of three or more antihypertensive drugs from different 
classes. Depending on populations studied and meth-
ods applied, the prevalence of treatment-resistant 
hypertension varies from 10% to 15% (1,2). Renal 
sympathetic nerves contribute to the development 
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 Rationale and design of the INSPiRED trial 139
and perpetuation of hypertension (3). Surgical tho-
racic sympathectomy and splanchnicectomy have 
been used in the past to reduce blood pressure. 
However, they were abandoned because of high 
morbidity and major adverse effects. Recently, 
catheter-based renal denervation (RDN) emerged 
as a potential treatment modality for resistant hyper-
tension (4,5). 
 The SYMPLICITY studies (4,5) showed that 
RDN was feasible in treating resistant hypertension. 
However, several issues remained unaddressed, 
which have been reviewed in detail elsewhere (6,7). 
The subsequently published literature includes sev-
eral observational studies and small series of cases. 
As summarized by a recent meta-analysis (8), among 
23 studies investigating RDN in resistant hyperten-
sive patients, only two (5,9) were randomized con-
trolled trials. One trial (9) was of low quality (10) 
and did not meet the CONSORT criteria (11). 
Three reports were case – control studies and all 
other studies were single-arm case studies without a 
control group. Therefore, the current evidence for 
RDN rests on only one randomized controlled trial 
(5). These limitations highlight the need for well-
conducted randomized controlled trials to evaluate 
the long-term effi cacy and safety of RDN in truly 
resistant hypertension patients. We therefore designed 
the Investigator-Steered Project on Intravascular 
Renal Denervation for Management of Drug-
Resistant Hypertension (INSPiRED). 
 Design 
 INSPiRED has a multicentre randomized controlled 
design. Eligible patients will be recruited at 16 
tertiary referral centres in Belgium and randomized 
to usual medical treatment (control group) or 
usual medical treatment plus RDN (intervention 
group). The trial consists of six stages (Figure 1): 
(i)  a screening visit , at which the patient ’ s eligibility 
will be checked according to inclusion and exclusion 
criteria, and informed consent will be obtained. 
(ii)  A run-in period , lasting 1 – 3 months to allow inves-
tigators to optimize medical treatment. During the 
run-in period, additional examinations will be 
performed to exclude secondary hypertension. 
Offi ce, home and the 24-h ambulatory blood pres-
sures will be recorded. The measurements obtained 
at the end of the run-in period will serve as baseline. 
(iii)  Stratifi cation and randomization : eligible patients 
will be stratifi ed by centre and age group (20 – 49 vs 
50 – 69), and subsequently randomized in a one-
to-one proportion to the control or intervention 
group. (iv)  RDN procedure : patients randomized to 
the intervention group will undergo RDN shortly 
after randomization, while continuing their antihy-
pertensive medications with dose adjustments if 
required; in the control group, patients will be main-
tained on optimized drug treatment. Six months 
after having been randomized, patients of the 
control group can cross over and undergo RDN. 
(v)  Follow-up at the participating centres will be 
scheduled at 1, 3 and 6 months after randomization 
(Figure 1). If patients of the control group cross 
over, they will be followed up at the same interval up 
to 6 months after the procedure. A visit 2 months 
after RDN is optional. (vi)  Long-term supervised or 
non-supervised follow-up will extend up to 36 months 
with visits planned at 6 monthly or annual intervals. 
Supervised follow-up refers to patients attending 
the INSPiRED clinical centres. Investigators will 
continue to collect information in patients not being 
followed up at the INSPiRED centres, so called 
non-supervised follow-up. 
 On 31 January 2014, the Ethics Committee of 
the Faculty of Medicine of the University of Leuven 
approved INSPiRED. The trial will start with a 
pilot phase at two centres (Cliniques Universitaires 
Saint-Luc, Bruxelles and University Hospital 
Leuven). The pilot phase aims to assess feasibility in 
terms of recruitment rate as a proportion of screened 
patients, to test the procedures as described in the 
protocol, and to evaluate the 1-month responses in 
24-h ambulatory blood pressure in 16 randomized 
Run-in
RDN
Control
Endpoint
assessment
6 m3 m1 m 36 m
Follow up
RDN (cross-over)
Long-term follow up
6 m 61 m
Stratification
and
randomization
Screening
63 m
 Figure 1.  Schematic representation of the INSPiRED trial. During the run-in period, antihypertensive drug treatment is optimized 
and secondary hypertension is excluded. Patients are randomized to renal denervation (RDN) or control. After randomization, optimized 
drug treatment is continued in both treatment arms, but can be adjusted according to the achieved blood pressure level. After assessment 
of the endpoints at 6 months, control patients can cross over to renal denervation. Follow-up visits are scheduled at 1, 3 and 6 months 
after randomization and at 1, 3 and 6 months after renal denervation in control patients crossing over with a visit at 2 months being 
optional. The long-term follow-up last up to 36 months after randomization. 
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140 Y. Jin et al.
patients, of whom eight (four at each centre) will 
undergo RDN and eight (four at each centre) will be 
randomly assigned to medical treatment. The results 
of this pilot trial will be forwarded to the Ethics 
Committees of the two centres. The expectation is 
that the INSPiRED protocol as piloted will roll over 
in the full trial without major changes. 
 Primary and secondary outcomes 
 The primary endpoints for effi cacy and safety are 
the baseline-adjusted between-group differences in 
24-h systolic blood pressure and in estimated glom-
erular fi ltration rate (eGFR), as estimated by the 
Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) equation (12). To compare changes 
in renal function with other studies, such as the 
SYMPLICITY trials (4,5), eGFR will also be com-
puted by the Modifi cation of Diet in Renal Disease 
(MDRD) formula (13). Secondary endpoints for 
effi cacy include the proportion of patients reaching 
and maintaining blood pressure control, defi ned as 
a 24-h blood pressure level below 130 mmHg sys-
tolic and 80 mmHg diastolic, a daytime blood pres-
sure below 135 mmHg systolic and 85 mmHg, a 
self-measured blood pressure at home below 135 
mmHg systolic and 85 mmHg, or an offi ce blood 
pressure below 140 mmHg systolic and 90 mmHg 
diastolic. Secondary endpoints for safety include acute 
and chronic procedural safety, a decline in eGFR by 
25% or more, a new renal arterial stenosis of over 60% 
confi rmed by renal angiogram at 6 months, as well as 
cardiovascular outcomes. Other secondary endpoints 
include the intensity of medical treatment, quality of 
life assessment and the cost-effectiveness analysis. 
 Sample size 
 To detect a 10-mmHg difference in systolic blood 
pressure between the randomized groups with the 
standard deviation set at 20 mmHg and a two-sided 
 p -value of 0.01 and 90% power, 480 patients would 
have to be screened and 240 randomized, assuming 
50% screening failures. Assuming a baseline-adjusted 
between-group difference of 10 ml/min/1.73 m 2 in 
eGFR and a standard deviation of 20 ml/min/1.73 m 2 , 
100 patients randomized per group should be suffi -
cient to reach 0.05 signifi cance with 95% power. 
 Selection of patients 
 The inclusion and exclusion criteria are listed in 
Table I. Eligible patients are 20 – 69 years old and 
have essential hypertension. The 24-h ambulatory 
blood pressure should be 130 mmHg systolic or 
80 mmHg diastolic or higher, while the patient is 
taking three or more antihypertensive medications 
from different classes, preferably including a diuretic 
(14). An aldosterone receptor antagonist and/or a 
betablocker should at least have been tried, unless 
contra-indicated. 
 Renal denervation 
 RDN will be performed using the EnligHTN TM  
multi-electrode denervation system (St Jude 
Medical, St. Paul, Minnesota, USA). This system 
allows four ablations to be performed simultane-
ously. One 60-s ablation will be delivered at the 
mid/distal segment of the renal artery with activa-
tion of the four electrodes making up the basket. 
In case of a long renal artery, a more proximal 
positioning of the basket will allow a second 
ablation of 60 s with activation of all or part of the 
electrodes. The same RDN procedure will be per-
formed at the main renal arteries of either side. 
Angiography will be performed to control the renal 
arterial anatomy after the procedure and to identify 
potential spasm between and after ablations. 
 Follow-up 
 Patients will be followed up to 6 months after ran-
domization (Figure 1) for assessment of the primary 
and secondary endpoints. Long-term supervised or 
non-supervised follow-up will continue up to 36 
months after RDN to evaluate the long-term safety 
 Table I. Criteria for patient selection in the INSPiRED trial. 
Inclusion criteria
Age    20 and    69 years
Essential hypertension
Treatment-resistant offi ce hypertension (   140/90 mmHg), 
while taking    3 antihypertensive drugs from different 
classes, preferably including a diuretic
An aldosterone receptor antagonist or betablockers should be 
attempted
Persistent offi ce hypertension (   140/90 mmHg) and 24-h 
ambulatory blood pressure    130/80 mmHg after 
optimization of antihypertensive drug treatment
eGFR    60 ml/min/1.73 m 2 at screening
Main renal arteries with diameter    4 mm and length    20 mm
Written informed consent
Exclusion criteria
Pregnancy
Secondary hypertension
Masked hypertension after optimization of treatment when 
the patient is considered for randomization
Unsuitable anatomy of renal arteries, including signifi cant 
(   50%) renal arterial stenosis, renal artery stent, or single 
functional kidney
Isolated systolic or isolated diastolic hypertension
Body mass index    40 kg/m 2 
Unstable diabetes mellitus
Major cardiovascular events within 6 months prior to 
enrolment
Any serious medical condition
Psychiatric illness or substance abuse
Patients on the waiting list of elective surgery
 Masked hypertension is a normal offi ce blood pressure 
(   140/90 mmHg) in the presence of 24-h ambulatory hyper-
tension (   130/80 mmHg). 
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 Rationale and design of the INSPiRED trial 141
and effi cacy of the procedure and to compare the 
incidence of events between randomized groups. 
 Ancillary studies 
 The INSPiRED study will offer the possibility to set 
up optional ancillary studies with a longitudinal 
design comparing the infl uence of randomized treat-
ment on various organ systems. A bio-bank of frozen 
serum and plasma samples obtained at different time 
points of the trial will be set up at the Studies Coor-
dinating Centre (SCC) in Leuven. All centres will 
perform echocardiography as part of routine clinical 
care. However, INSPiRED centres can also opt to 
participate in an ancillary echocardiographic study, 
using the protocols as implemented in FLEMish study 
on ENVironment Genes and Health Outcomes (FLE-
MENGHO ) and in the European Project of Genes 
in Hypertension (EPOGH) (15,16). Structure and 
function of the large arteries, the microcirculation and 
endothelial function can also be evaluated, following 
the standard operational procedures implemented in 
the FLEMENGHO and EPOGH studies (17). 
 Management of hypertension 
 Antihypertensive treatment 
 To optimize blood pressure lowering drug treat-
ment, the investigators will follow current guidelines 
(18,19). Treatment strategy will be standardized as 
follows: (i) by using combinations of antihyperten-
sive drugs with different mode of action in line 
with the AB/CD algorithm (18), as illustrated in 
Figure 2; (ii) by using antihypertensive agents with 
a long duration of action, so-called forgiving drugs 
(20); (iii) by enhancing adherence via reduction of 
the pill load and by prescription of single-pill com-
bination tablets, including two or three antihyper-
tensive agents in varying doses; (iv) for each 
antihypertensive drug, the highest dose that does not 
produce side-effects will be prescribed; (v) antihy-
pertensive drug combinations should preferably 
include a diuretic; (vi) if not contra-indicated, 
aldosterone receptor antagonists and betablockers 
will at least be attempted. After RDN, blood 
pressure lowering drug treatment will be maintained 
at an intensity required to keep the patient ’ s 
blood pressure within or as close as possible to the 
normotensive range (18,19,21). 
 Lifestyle 
 Lifestyle changes will be recommended and rein-
forced during the whole trial, including stopping 
smoking, moderation of excessive alcohol intake, 
regular physical activity, weight reduction in over-
weight or obese patients, dietary measures to control 
dyslipidaemia, and a moderation of salt intake (22). 
 Figure 2.  INSPiRED algorithm for adjustment if antihypertensive drug treatment. Recommendation for combining blood-pressure 
lowering drugs according to the ABCD rule. Modifi ed from: JBS 2: Joint British Societies ’ guidelines on prevention of cardiovascular 
disease in clinical practice. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular 
Society, The Stroke Association. Heart 2005;91: supplement 5:v1 – 52. Copyright  © 2005 BMJ. Reproduced with permission from BMJ 
Publishing Group Ltd. 
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 Measurements 
 Table II lists measurements to be obtained by visit. 
 Blood pressure 
 In INSPiRED, the clinic blood pressure, self-mea-
sured home blood pressure and 24-h ambulatory 
blood pressure will be measured according to the 
recommendations of the European Society of 
Hypertension (19,23), using validated devices. If at 
the screening visit systolic and diastolic blood pres-
sure differences between the left and right arm are 
less than 10 mmHg, the investigator will select the 
non-dominant arm for all blood pressure measure-
ments throughout the study. Otherwise, the arm 
giving the highest blood pressure readings must be 
chosen. A standard cuff of 22    12 cm will be used 
if the arm circumference is less than 32 cm. For 
arms with a larger circumference, cuffs with a blad-
der size of at least 31    15 cm will be used. 
 Clinic blood pressure will be measured after the 
patient has been seated for 5 min in a quiet room. 
Three consecutive blood pressure readings at inter-
vals of 30 – 60 s will be obtained while the patient 
remains in the sitting position. The investigator will 
then ask the patient to stand up and obtain two 
additional blood pressure readings. The 24-h ambu-
latory blood pressure recordings should include at 
least 20 readings for the daytime or awake blood 
pressure and seven readings for the night-time or 
asleep blood pressure (23). The whole recording 
should cover at least 20 h with no interval between 
two successive reading longer than 3 h. On the 
day of the recording, the patients must complete a 
diary card, from which it should be possible to 
retrieve the timing of meals and intake of drugs, 
and when sleep at night started and ended. Self-
measurement of blood pressure at home will be 
done according to current guidelines (24,25) using 
properly validated devices. The investigators will 
educate patients in the proper use of the home 
monitors. Patients should complete a diary provid-
ing information on the timing and values of blood 
pressure and heart rate. Patient will be requested to 
obtain two consecutive blood pressure readings in 
the sitting position, twice daily, in the morning 
between 06:00 and 10:00 h before breakfast and 
intake of medications, and in the evening between 
18:00 and 22:00 h, during the 7 days preceding 
each clinical visit. The self-measured home blood 
pressure is the average of all blood pressure readings 
of the last six days, discarding the readings of the 
fi rst day (25). 
 Adherence 
 In the INSPiRED trial, several instruments will be 
implemented to assess adherence. A simple question-
naire with eight questions (26) will be used to assess 
adherence to antihypertensive drugs. Jung and 
co-workers (27) developed a liquid chromatography – 
mass spectrometric method that allows all anti-
hypertensive drugs or their metabolites in a single 
urine sample to be detected in a qualitative manner. 
This approach will be mandatory in INSPiRED. A 
urine sample of 10 ml will be collected and stored at 
  18 ° C for this purpose. Investigators will remain 
blinded to these measurements until all patients 
have completed the randomized part of the study. 
 Renal artery imaging 
 INSPiRED will apply state-of-the-art non-invasive 
imaging of the renal arteries before randomization 
and during the follow-up. Multi-detector computed 
tomographic angiography (MDCTA) is the most 
effective method and will be the technique of choice. 
MDCTA has the advantage of high spatial and tem-
poral resolution, widespread availability, implantable 
device compatibility and easy technical reproducibility 
 Table II. Measurements by visit. 
Measurement Screening Run-in Baseline Follow-up Long-term follow-up
Offi ce visit VS VR V0 V1 V2 V3 V6 SFU NSFU
Offi ce blood pressure X X X X X X X X
Ambulatory blood pressure X X X X X X
Home blood pressure X X X X X X
Adherence X X X X X X X
Urinary proteomics X X X X X X X
Imaging of renal artery X X
Electrocardiogram X X X
Heart rate variability X X
Echocardiogram X X X
Quality of life X X X X X X X
Follow-up of morbidity and mortality X X X X X X
 VS is the screening visit, VR refers to the visits during the run-in period. V0 is the visit after which eligible patients are stratifi ed and 
randomized to control or intervention. V1, V3 and V6 indicate the visits at 1, 3 and 6 months after randomization or after renal denervation 
in patients crossing over from control to intervention. V2 is optional. SFU and NSFU indicate supervised and non-supervised follow-up 
beyond 6 months. 
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(28,29). MDCTA can determine the position and 
orientation of renal arteries, precisely measure the 
length and diameter of the renal arteries, and visual-
ize lesions and stenosis of the renal arteries. In cases 
of contra-indications to MDCTA or iodine injec-
tion, contrast-enhanced magnetic resonance imag-
ing (MRI) will be used. 
 Sympathetic modulation 
 Assessment of heart rate variability is a possible way 
to investigate changes in autonomous nervous tone 
after RDN. The high-frequency component of heart 
rate variability depends on vagal activity, while the 
low-frequency power predominantly represents sym-
pathetic modulation (30,31). Heart rate variability 
will be assessed at baseline and at the 6-month fol-
low-up visit, based on 15-min ECG recordings in 
the supine and standing position according to a pub-
lished standardized protocol (32,33). To analyse the 
ECG recordings, a software program, developed by 
Aubert and colleagues (34) will be used. 
 Stimulation of the renal nerves before and after 
ablation allows us to monitor the haemodynamic 
responses in terms of heart rate and blood pressure. 
Chinushi and coworkers (35) applied this technique 
in animals and found that before RDN, electric 
stimulation was followed by signifi cant increases in 
blood pressure, heart rate and heart rate variability, 
as well as circulating epinephrine and norepineph-
rine, while after the procedure these responses to 
renal nerve stimulation were signifi cantly blunted at 
the denervated renal artery, but remained unchanged 
after application of the same stimuli to the contral-
ateral intact artery. Their study demonstrated that 
electric stimulation may be a valuable tool to moni-
tor the effi cacy of RDN and provide insights into 
the mechanisms underlying the effects of RDN. 
During the course of INSPiRED, we will try to 
develop stimulation of the renal nerves as a novel 
way to assess completeness of disruption of the renal 
nerves in selected centres. 
 Urinary proteomics 
 Recent publications (36) showed the feasibility of 
developing multidimensional classifi ers based on the 
urinary proteome that are associated with chronic 
kidney disease. In the FLEMENGHO population, 
we observed that the urinary proteome refi nes the 
diagnosis of existing or progressing renal dysfunction 
and predicts cardiovascular complications (unpub-
lished observation). In INSPiRED, investigators will 
collect spot urine samples at each visit for analysis of 
the urinary proteome by means of the highly innova-
tive technology of capillary electrophoresis coupled 
to mass spectrometry (37), developed by Mischak 
and colleagues (Mosaiques Diagnostics and Thera-
peutics AG, Hannover, Germany). This technology 
allows the detection of renal dysfunction at an early 
subclinical stage. 
 Morbidity and mortality 
 Events in INSPiRED will comply with defi nitions as 
implemented in previously published randomized 
clinical trials (38,39). 
 Quality of life and cost-effectiveness 
 The quality of life of the patients will be assessed at 
baseline and at each visit during follow-up, using the 
EQ-5D questionnaires (http://www.euroqol.org/). 
Data collected by the EQ-5D questionnaire can be 
converted into the information provided by the 
SF-36 instrument. This questionnaire is of particu-
lar importance for the economic evaluation and the 
cost-effectiveness of the RDN. The cost-effectiveness 
analysis will be conducted from the perspective of 
the Belgian healthcare system, including both the 
direct and indirect costs of the intervention. The 
procedural costs will be balanced against the use 
of medical resources following RDN, including 
outpatient visits, hospital admissions, diagnostic 
procedures, interventions and medications. Adverse 
events and the incidence fatal and non-fatal events 
will be recorded for the economic analysis. 
 Data management and statistical analysis 
 The SCC in Leuven will be in charge of the man-
agement of the trial, the stratifi cation and random-
ization of patients, database management and 
statistical analyses. For data management and sta-
tistical analysis, the SCC will use SAS software 
(SAS Institute, Cary, NC, USA). The main analysis 
will be done using the intention-to-treat dataset. 
This dataset will include all randomized patients 
who underwent the procedure and who have at least 
one endpoint assessed after the randomization. The 
dataset for observational analyses include complete 
information on all available patients from screening 
onwards, irrespective of whether they were random-
ized. These data will be useful for the analyses 
attempting to describe the characteristics of patients 
that will make it to RDN. The per-protocol dataset 
is a subset of the intention-to-treat dataset exclud-
ing patients randomized but not complying with all 
inclusion and exclusion criteria, patients deviating 
from the study protocol to such extent that they 
might introduce bias in the intention-to-treat anal-
ysis, and the post-procedural data from patients 
randomized to the control group, but crossing over 
to RDN. All statistical tests will be two-sided. 
 The primary and secondary endpoints measured 
on a continuous scale will be analysed using mixed 
models. Comparisons between groups will be done 
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with adjustment for baseline. The fi xed effects in the 
model include randomization group and confound-
ers. To account for the correlation between a patient ’ s 
repeated blood pressure measurements, the model 
will also include patient-level random effects. 
Centre-level random effects might be included to 
account for the possible correlation of measurements 
between patients recruited within the same centre. 
Binary endpoints, such as blood pressure control 
over time, will be analysed by means of McNemar ’ s 
test and hierarchical mixed-effects logistic regression 
models. For endpoints that occur in a given order, 
the method proposed by Finkelstein  & Schoenfeld 
(40) might be used to combine a time to event and 
longitudinal event, so that if there is a substantial 
difference between treatments in either outcome, the 
null hypothesis will be rejected. 
 Discussion 
 INSPiRED is an investigator-steered randomized 
controlled trial designed to assess the effi cacy and 
safety of RDN. It is powered to address whether 
RDN on top of usual medical therapy is effective and 
safe for treating resistant hypertension compared 
with usual medical therapy alone. The primary and 
secondary endpoints will be assessed 6 months after 
randomization, but patients will remain in follow-up 
up to 36 months. 
 We decided to launch this new trial, because we 
strongly believe that previous trials did not select 
patients most likely to respond to RDN and did not 
assess effi cacy and safety according to the best evi-
dence available from previous studies and current 
clinical experience in various European countries. 
The recent announcement that SYMPLICITY 
HTN-3 failed to reach its primary endpoint of effi -
cacy confi rms the need for a radically different 
approach. Furthermore, as stated in the published 
analysis plan, failure to meet the primary endpoint 
of effi cacy will preclude analysis of the secondary 
endpoint based on 24-h systolic blood pressure. The 
parallel announcement that the primary endpoint 
for safety (including all-cause mortality, end-stage 
renal disease and major cardiovascular complica-
tions) was achieved is in no way unexpected and of 
little relevance in the absence of substantial blood 
pressure lowering effi cacy. It does not rule out sub-
tle changes in eGFR, such as those observed in the 
3year follow-up of SYMPLICITY HTN-1 patients 
(41), in whom eGFR fell from 83.6 to 74.3 ml/
min/1.73 m 2 ( p    0.05). The SYMPLICITY HTN-3 
debacle highlights that contrary to the prevailing 
opinion of the manufacturers, RDN can never 
replace properly instituted and adjusted treatment 
with antihypertensive drugs. However, the failure of 
SYMPLICITY HTN-3 creates new opportunities 
for well-designed randomized controlled trials of 
RDN in an attempt to identify the  “ niche ” of patients, 
who are likely to benefi t from the procedure. 
 INSPiRED is geared to reach its goal because 
of its unique design features: (i) a stringent selection 
of patients, excluding patients with chronic kidney 
disease stage 3 (   60 ml/min/1.73 m 2 ) and patients 
with isolated systolic or isolated diastolic hyperten-
sion, but including patients with multiple renal 
arteries with suitable anatomy; (ii) the age range 
will be limited from 20 to 69 years; (iii) drug opti-
mization with assessment of adherence throughout 
the study, use of variable single-pill combinations 
and long acting  “ forgiving ” drugs (20); (iv) 24-h 
ambulatory blood pressure is applied for patient 
selection and for assessment of the primary effi cacy 
endpoint; (v) the primary endpoint for safety is 
based on eGFR estimated according to the CKD-
EPI equation; (vi) state-of-the-art renal artery 
imaging by computerized tomographic angiography 
with the possibility of using MRI if the former tech-
nique is contra-indicated; (vii) validation of urinary 
proteomic biomarkers to predict blood pressure 
responses and changes in renal function; (viii) The 
trial includes an assessment of quality of life and an 
economical analysis; (ix) extension of the follow-
up beyond 6 months up to 3 years to assess the 
incidence of morbidity and mortality; (x) use of 
RDN systems with a design different from the 
SYMPLICITY catheter, and (xi) use of heart rate 
variability in all patients and renal nerve stimulation 
in selected centres to assess the completeness of 
RDN acutely and chronically. 
 In conclusion, INSPiRED has unique design 
features that sets this trial apart from all other 
studies of RDN in treatment-resistant hypertension. 
INSPiRED will generate long-term effi cacy and 
safety data, identify the subset of treatment-resistant 
hypertensive patient responsive to RDN, and provide 
information on cost-effectiveness. The information 
acquired during the INSPiRED trial will inform 
guideline committees and health policy makers. 
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